Status:
NOT_YET_RECRUITING
A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Relapsed/Refractory Indolent NHL
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The study is being conducted to evaluate the reasonable dosage, efficacy and safety of Linperlisib in combination with rituximab in subjects with relapsed/refractory (R/R) indolent non-hodgkin lymphom...
Eligibility Criteria
Inclusion
- Patients received at least 1 lines of systemic therapy
- Previously received anti- CD20 treatment
- Subjects must have at least one bi-dimensionally measurable lesion (nodal site Ldi \> 1.5 cm or extranodal site Ldi \> 1.0cm)
- Patients must have an acceptable organ function
Exclusion
- Previously treated with PI3K inhibitors
- Unresolved toxicity of CTCAE grade \> 1 from prior anti-lymphoma therapy
- Chemotherapy or other antitumor therapy within 14 days before starting cycle one
- Significant concurrent medical disease or condition which according to the investigators' judgement
- Active hepatitis B, C or HIV infection
- Infection requiring treatment 2 weeks prior to the first dosing
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06981988
Start Date
June 1 2025
End Date
February 1 2027
Last Update
May 21 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.